文献速递产科

宫内真空诱导止血装置在产后出血管理中的真实世界应用

Real-World Utilization of an Intrauterine, Vacuum-Induced, Hemorrhage-Control Device.
PubMed 文献 · Obstet Gynecol · 2023-09-13

研究评估美国FDA批准的宫内真空诱导止血装置在产后出血管理中的真实世界有效性与安全性,纳入美国16个中心2020年10月至2022年3月的800例产妇(阴道分娩530例、剖宫产270例)。阴道分娩治疗成功率92.5%、剖宫产83.7%,未见子宫穿孔或死亡,安全性特征与注册试验一致。

要点

  • 阴道分娩治疗成功率92.5%,剖宫产83.7%,孤立性子宫收缩乏力时分别为95.8%和88.2%。
  • 阴道分娩严重不良事件13例(2.5%),剖宫产21例(7.8%);3例(0.4%)可能与装置或操作相关。
  • 阴道分娩和剖宫产的中位留置时间分别为3.1小时和4.6小时,均实现快速有效止血。

核心结论

  • 在真实世界环境中,阴道分娩和剖宫产使用FDA批准的宫内真空诱导止血装置均能实现快速有效的止血。
  • 安全性特征与注册试验(NCT02883673)中观察到的一致,严重不良事件或器械不良效应的性质和严重程度符合产后出血背景下的预期。
  • 该装置是管理危及生命状况的重要新工具,及时使用可能有助于改善产科出血结局。

研究设计与样本

  • 美国16个中心参与的观察性上市后注册病历回顾研究,时间范围为2020年10月至2022年3月。
  • 共800例接受该装置治疗的产妇,其中阴道分娩530例,剖宫产270例。
  • 主要有效性结局为治疗成功,定义为置入后出血得到控制且无治疗升级或出血复发。
  • 按分娩方式汇总所有结局;按出血原因(所有原因、任何子宫收缩乏力、孤立性子宫收缩乏力、非子宫收缩乏力)汇总治疗成功率。

主要发现

  • 94.3%的病例存在子宫收缩乏力(单独或与其他原因合并)。
  • 置入装置时中位总失血量:阴道分娩为1050 mL,剖宫产为1600 mL。
  • 所有出血原因中,治疗成功率阴道分娩为92.5%,剖宫产为83.7%;孤立性子宫收缩乏力时分别为95.8%(n=307)和88.2%(n=220)。
  • 中位留置时间阴道分娩为3.1小时,剖宫产为4.6小时。
  • 阴道分娩中13例(2.5%)报告14例严重不良事件;剖宫产中21例(7.8%)报告22例严重不良事件;3例(0.4%)严重不良事件被认为可能与装置或操作相关;未报告子宫穿孔或死亡。

关键数值与推荐

  • 原文未报告

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the real-world effectiveness and safety of a U.S. Food and Drug Administration (FDA)-cleared intrauterine vacuum-induced-hemorrhage control device for postpartum hemorrhage (PPH) management. METHODS: Sixteen centers in the United States participated in this observational, postmarket registry medical record review (October 2020 through March 2022). The primary effectiveness outcome was treatment success , defined as bleeding control after insertion with no treatment escalation or bleeding recurrence. Additional outcomes included blood loss, time to device insertion, indwelling time, bleeding recurrence, and time to bleeding control. Treatment success and severe maternal morbidity measures (transfusion of 4 or more units of red blood cell, intensive care unit admission, and hysterectomy) were evaluated by blood loss before insertion. To assess safety, serious adverse events (SAEs) and adverse device effects were collected. All outcomes were summarized by mode of delivery; treatment success was summarized by bleeding cause (all causes, any atony, isolated atony, nonatony). RESULTS: In total, 800 individuals (530 vaginal births, 270 cesarean births) were treated with the device; 94.3% had uterine atony (alone or in combination with other causes). Median total blood loss at device insertion was 1,050 mL in vaginal births and 1,600 mL in cesarean births. Across all bleeding causes, the treatment success rate was 92.5% for vaginal births and was 83.7% for cesarean births (95.8% [n=307] and 88.2% [n=220], respectively, in isolated atony). Median indwelling time was 3.1 hours and 4.6 hours, respectively. In vaginal births, 14 SAEs were reported among 13 individuals (2.5%). In cesarean births, 22 SAEs were reported among 21 individuals (7.8%). Three (0.4%) SAEs were deemed possibly related to the device or procedure. No uterine perforations or deaths were reported. CONCLUSION: For both vaginal and cesarean births in real-world settings, rapid and effective bleeding control was achieved with an FDA-cleared intrauterine vacuum-induced hemorrhage-control device. The safety profile was consistent with that observed in the registrational trial (NCT02883673), and SAEs or adverse device effects were of the nature and severity expected in the setting of PPH. This device is an important new tool for managing a life-threatening condition, and timely utilization may help to improve obstetric hemorrhage outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04995887.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Goffman D, Rood KM, Bianco A, et al. Real-World Utilization of an Intrauterine, Vacuum-Induced, Hemorrhage-Control Device. Obstet Gynecol. 2023. PMID: 37713322. doi:10.1097/AOG.0000000000005366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。